Accrol Group Holdings plc is a leading independent tissue converter, manufacturing toilet rolls, kitchen rolls, facial tissues and AFH products to supply retailers throughout the UK. Accrol imports parent reels from around the world and converts them into finished goods at the Company’s 350,000 sq. ft. manufacturing, storage and distribution facility in Blackburn, Lancashire. Accrol currently manufactures approximately 17 million units per week and supplies some of the UK’s largest retailers.

Accrol Group Holdings plc is listed on AIM, the growth market of the London Stock Exchange.

The Company was incorporated and registered in England and Wales on 30 April 2014 under the Act with registered number 9019496 as a private company limited by shares with the name Aghoco 1220 Limited. The name of the Company was changed to Accrol Group Holdings Limited on 1 August 2014. The Company was re-registered as a public limited company with the name Accrol Group Holdings plc on 1st June 2016. Accrol Group Holdings plc’s main country of operation is the UK.

The Company, and the Group, trade under the name “Accrol Papers”.

A £132 grand spend by the CEO shows confidence. Lets hope for a good future.

AGM -NOTICE IS GIVEN that the Annual General Meeting of Accrol Group Holdings plc will be held at Stanley House Hotel, Mellor, Lancashire BB2 7NP on 30 September 2016 at 11am for the following purposes:

AGM notes

New high. :-))

Accrol general meeting. some good warehouse pictures


Next Event
30/04/2017
Next year end (to be reported)

Good large 25,000 and 100,000 buys. On the way now.


http://www.moneyam.com/trades/ACRL

Indeed well on the way and it's not going to drop to my target to buy more at £1.20, this I think will easily double.

Going to look at any dips (I doubt there will be any) and top up, better to average up than average down!

DYOR GLA :-)

ST of IC today - When a director splashes out over £100,000 buying shares in his company it’s always worth further investigation. I didn’t have to do much research in the case of Accrol (ARCL:140p), the Aim-traded Blackburn-based maker of toilet rolls, kitchen rolls and facial tissues, as this is a business I know well, having recommended buying the shares when they floated at 100p in the summer ('Clean up with Accrol', 6 Jun 2016), and subsequently reiterated that advice at 118p (‘Brexit winners’, 1 Aug 2016).
The fact that chief executive Stephen Crossley has just invested £132,000 of his own money buying 100,000 shares at a 32 per cent premium to the float price tells a story about Accrol’s trading prospects. Higher consumer demand for private-label products is helping drive ongoing strong sales growth from discount retailers, a segment where the company has a 35 per cent market share, as is management’s ability to cross sell multiple products to new clients. Maiden results have done nothing to alter my earlier positive stance: like-for-like sales rose by 17 per cent to £118m in the year to end April 2016, and analyst Mike Allen at house broker Zeus Capital expects Accrol to maintain this heady growth rate in the current financial year, pencilling in revenue of £138m.
On this basis, expect cash profits to rise by around 10 per cent to £16.4m to produce pre-tax profits of £13.4m and EPS of 11.5p in the 12 months to end April 2017. This means Accrol’s shares are being valued on a forward PE ratio of 12, a rating that fails to acknowledge its potential to continue to grow earnings at a double digit rate for years to come. Indeed, for the following year to end April 2018, Mr Allen believes that Accrol can lift revenues to £156m, increase both cash profits and pre-tax profits by £2.2m, and deliver EPS of 13.4p to reduce the forward PE ratio to 10.5. I am comfortable with those estimates.
The current rating also fails to fully reflect the company’s cash generation. Indeed, net debt is expected to fall to £16m by end April 2017, a sum equivalent to one times cash profits and less than 30 per cent of shareholders funds. So, with profits growing strongly, and the balance sheet modestly geared, the board can recycle cashflow into a progressive dividend. Guidance is for a 6p a share payout in the current year, implying the shares offer a 4.4 per cent prospective dividend yield, rising to around 6.25p a share the year after.
In the circumstances, it’s hardly surprising my 130p target price has proved too conservative and I now feel that a rating of 12 times EPS estimates of 13.4p for the 12 months to end April 2018 is a more realistic valuation. This implies a new target price of 160p, and one that more accurately takes into account Accrol’s low balance sheet gearing, and prospects of delivering double digit earnings growth. Buy.

Details of dividend below -



EVENT
TIMING
RECENT/UPCOMING DATES
Financial year
Year end 30 April
Half year end 31 October

Results published
Full year preliminary results
Our preliminary results for the year ending 30 April 2016 were released on 22 July 2016. These are available on the ‘Company Reports and Presentations’ page and in the ‘Regulatory News’ section of our website.

Interim results
Our interim results for the half year ending 31 October 2016 will be released mid-January 2017.
AGM
Late September
Our 2016 AGM was held on 30 September 2016 at 11am at Stanley House Hotel, Mellor. The AGM Result can be found on the ‘Regulatory News’ section of our website.
Dividends
Interim dividend record date November, paid January
An interim dividend of 1/3 is expected to be paid in January 2017.

Final dividend record date May, paid September (subject to shareholder approval).
A final dividend of 2/3 per share for the year ending 30 April 2017 is expected to be paid September 2017.

Shorting activity = very low


On Thursday, Accrol Group Holdings PLC (ACRL:LSE) closed at 121.50, -13.83% below its 52-week high of 141.00, set on Oct 11, 2016.

Pre-close trading statement
RNS
RNS Number : 4344O
Accrol Group Holdings PLC
07 November 2016
 
This announcement contains inside information
7 November 2016
 
Accrol Group Holdings plc ("Accrol" or "the Company")
Pre-close trading statement
 
Accrol Group Holdings plc, the AIM listed leading independent tissue converter, is pleased to provide the following update on trading.   
The business has made good progress since the start of this financial year and trading has been in line with our expectations. During the six months ended 31 October 2016, the Company has continued to win new business with existing customers in addition to the previously announced new £10m contract gain, which we can now confirm is Lidl.
Installation of two high-speed converting lines in our new 168,000 sq. ft. manufacturing facility in Leyland is well underway and will increase our total capacity to 143,000 tonnes per annum. The premises will initially house the two high speed tissue converting lines we purchased in April 2016 and the increased capacity will support our continued growth with both Discounters and Major Multiples in the UK.
We continue to follow our hedging policy to mitigate adverse movements in Sterling against the US$ and Euro. Following our significant purchase of dollars pre-Brexit, we have increased our facilities and we continue to closely monitor the Company's forward currency positions.
We remain confident in the outlook for the full year and that the strong cash flows generated by the business will support our progressive dividend policy and underpin our continued growth.
The Company's interim results will be announced on Thursday 5th January, 2017.
Steve Crossley, Accrol's CEO, commented:
 
"Since the start of this financial year we have made good progress on our strategic aims and we are increasing our production capacity to enable us to take advantage of new opportunities as they arise.
 
"We are pleased with the new business that we have won since the start of the financial year and with progress on the manufacturing facility in Leyland, Lancashire and look forward to the future with confidence."
 
Ends

ST of IC - And as I pointed out when I first recommended buying the shares when they floated at 100p in the summer ('Clean up with Accrol', 6 Jun 2016), the company has reported compound annual sales growth of 16 per cent over the past four years, and profitably, too. Cash profit increased by 14 per cent in the period to £15m in the 12 months to the end of April 2016, and analysts expect a rise to £16.4m in the current financial year to produce pre-tax profit of £13.4m, EPS of 11.5p and support a dividend of 6p a share. On that basis, the shares are rated on 11 times earnings estimates, and offer a prospective dividend yield of 4.7 per cent, hardly an exacting rating for a company that has a track record of delivering double-digit profit growth and one targeted at the high growth discount sector. Indeed, Aldi and Lidl now have over 10 per cent of the UK retail market and are opening five times as many new stores as all their 'Big Four' rivals combined, so expect them to make further market share gains in the coming years.
So, having raised my target price to 160p when I last rated the shares a buy at 140p ('High fives', 4 Oct 2016), I have no hesitation reiterating that advice. Buy.

ST of IC - And as I pointed out when I first recommended buying the shares when they floated at 100p in the summer ('Clean up with Accrol', 6 Jun 2016), the company has reported compound annual sales growth of 16 per cent over the past four years, and profitably, too. Cash profit increased by 14 per cent in the period to £15m in the 12 months to the end of April 2016, and analysts expect a rise to £16.4m in the current financial year to produce pre-tax profit of £13.4m, EPS of 11.5p and support a dividend of 6p a share. On that basis, the shares are rated on 11 times earnings estimates, and offer a prospective dividend yield of 4.7 per cent, hardly an exacting rating for a company that has a track record of delivering double-digit profit growth and one targeted at the high growth discount sector. Indeed, Aldi and Lidl now have over 10 per cent of the UK retail market and are opening five times as many new stores as all their 'Big Four' rivals combined, so expect them to make further market share gains in the coming years.
So, having raised my target price to 160p when I last rated the shares a buy at 140p ('High fives', 4 Oct 2016), I have no hesitation reiterating that advice. Buy.

Should you ditch Unilever in favour of fast-growing small-cap Accrol?
By Peter Stephens | Fool.co.uk – Mon, Nov 7, 2016 11:23 GMT
Share



Print
Companies:
Accrol Group Holdings Plc
Unilever PLC
RELATED QUOTES
Symbol
Price
Change
ACRL.L
126.00
0.00

ULVR.L
3,382.00
+21.50


Today's update from Accrol (LSE: ACRL) shows that the company is doing all the right things. The tissue specialist (that's kitchen towel, facial tissues and loo roll to you and I) is certainly performing in line with expectations and has excellent growth prospects. But does this mean that it's a better buy than consumer goods peer Unilever (LSE: ULVR)? It's a tough contest against the consumer goods giant. Let's take a look...
New business wins
Accrol's performance in the first six months of the current financial year shows that its strategy is performing well. It has been able to win new business with existing customers while also gaining new contracts such as the £10m deal with Lidl. Accrol is in the process of installing two high-speed converting lines in its new manufacturing facility. This will significantly increase its capacity and support long-term growth, especially with both discounters and major multiples in the UK.
In fact, Accrol could be a major beneficiary of Brexit. The UK economy could endure a challenging period that may end in inflation being higher than wage growth. This could lead to increased pressure on disposable incomes, which may cause shoppers to trade down to cheaper supermarkets and cheaper brands. This could increase demand for Accrol's products and act as a positive catalyst on its future growth.
Accrol is expected to increase its bottom line by 53% in the current year and by a further 22% next year. This is an excellent rate of growth and yet the market doesn't yet seem to have fully priced it in. For example, Accrol trades on a price-to-earnings growth (PEG) ratio of 0.4, which indicates that capital gain prospects are high.
The outlook for Accrol is brighter than for consumer goods peer Unilever. It's forecast to grow its bottom line by 5% in the current year and by a further 10% next year. This puts Unilever on a PEG ratio of 1.9. While this is attractive on an absolute basis, relative to Accrol, Unilever seems to be significantly overvalued at first glance.
However, Unilever offers a much lower risk profile than Accrol. For starters, it's a much more diversified business, with Unilever selling a wide range of goods that enjoy a high degree of customer loyalty. Unilever also has greater geographical diversity than Accrol, which means that its performance should prove to be more stable over the long run.
Unilever's financial firepower is also more impressive than that of Accrol. This means that Unilever is better positioned to invest for future growth, for example in the M&A arena. And with Unilever having a dividend yield of 3.2% which is covered 1.5 times by profit, it has far superior income potential to Accrol, the latter of which currently pays no dividend.
While Accrol is a worthy investment, Unilever's risk/reward profile is superior. Therefore, selling Unilever to buy Accrol doesn't seem to be a wise move at the present time.
But should you sell Unilever for this top growth stock?

Someone clearly buying in, in 18k, 25k and 50k lots. :-))

Someone clearly buying 18k, 25k and 50k lots. :-))

e-mail to me from the company today regarding the dividend -

So sorry to have taken such long time to respond but we were still sorting out the dates of payment etc.

I now have it confirmed that the shares will become ex dividend on 12 January 2017. The interim dividend will be paid to Members of the Registry at close of business on 13 January 2017.

One again, apologies for the delay.

Thanks
Kathleen

Thank you dreamcatcher it's in the diary, appreciate all your posts very helpful....

I have waited a couple of weeks for the info. Mind you the company always answer. Cheers stevesham.

Notice of interim results date change
RNS
RNS Number : 7679R
Accrol Group Holdings PLC
14 December 2016
 
14 December 2016
 
Accrol Group Holdings plc (the "Company" or "Accrol")
Notice of interim results date change
 
Accrol Group Holdings plc, the AIM listed leading independent tissue converter, is pleased to announce that its interim results will be announced earlier than previously reported, now on Wednesday 4 January 2017.
A presentation to analysts will take place at 9.30am on the 4th January at Camarco's offices at 107 Cheapside, London, EC2V 6DN. Please contact Camarco on the details below for further information

Now there is interesting I wonder why?

Do we think they have some great results they need to get into the market to speed up progress? maybe a move from AIM? maybe record results and can't wait to announce an amazing dividend, whatever it is, my belief is it will be amazing